Baricitinib
Janus-Associated Kinase (Jak) Inhibitors
Sold as OLUMIANT
- Drug class
- Janus-Associated Kinase (Jak) Inhibitors
- Availability
- See label
- Routes
- Oral
- Markets covered
- 3
- Products on record
- 6
Overview
Baricitinib is an active pharmaceutical ingredient in the Janus-Associated Kinase (Jak) Inhibitors group (L04AF). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 3 | May 22, 2026 |
| CA Canada | Health Canada | 2 | March 13, 2026 |
| EU European Union | EMA | 1 | May 7, 2026 |
GBUnited Kingdom· MHRA
3 products
Uses
Rheumatoid arthritis Baricitinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs).
1 for available data on different combinations). Atopic dermatitis Baricitinib is indicated for the treatment of moderate to severe atopic dermatitis in adult and paediatric patients 2 years of age and older who are candidates for systemic therapy.
1). Juvenile idiopathic arthritis Baricitinib is indicated for the treatment of active juvenile idiopathic arthritis in patients 2 years of age and older who have had an inadequate response or intolerance to one or more prior conventional synthetic or biologic DMARDs: - Polyarticular juvenile idiopathic arthritis (polyarticular rheumatoid factor positive [RF+] or negative [RF-], extended oligoarticular), - Enthesitis-related arthritis, and - Juvenile psoriatic arthritis.
CACanada· Health Canada
2 products
How to take
2 Recommended Dose and Dosage Adjustment 01/2024 7 WARNINGS AND PRECAUTIONS, Malignancies 06/2022 7 WARNINGS AND PRECAUTIONS, Major Adverse Cardiovascular Events 06/2022 7 WARNINGS AND PRECAUTIONS, Thrombosis 06/2022 7 WARNINGS AND PRECAUTIONS, Laboratory Parameters, Creatine phosphokinase 01/2024 7 WARNINGS AND PRECAUTIONS, Monitoring and Laboratory Tests, Renal 01/2024 TABLE OF CONTENTS Sections or subsections that are not applicable at the time of authorization are not listed.
8 Olumiant (baricitinib) tablets Page 3 of 55
This is not medical advice. Consult a qualified healthcare professional.
Side effects & warnings
EUEuropean Union· EMA
1 product
Uses
Rheumatoid arthritis Baricitinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs).
1 for available data on different combinations). 3 Atopic dermatitis Baricitinib is indicated for the treatment of moderate to severe atopic dermatitis in adult and paediatric patients 2 years of age and older who are candidates for systemic therapy.
1). Juvenile idiopathic arthritis Baricitinib is indicated for the treatment of active juvenile idiopathic arthritis in patients 2 years of age and older who have had an inadequate response or intolerance to one or more prior conventional synthetic or biologic DMARDs: - Polyarticular juvenile idiopathic arthritis (polyarticular rheumatoid factor positive [RF+] or negative [RF-], extended oligoarticular), - Enthesitis-related arthritis, and - Juvenile psoriatic arthritis.
Drug interactions
Known interactions involving Baricitinib. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 267. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PLGB148950339 · revised May 22, 2026
- [2]Health Canada (DPD) · 02480018 · revised March 22, 2025
- [3]European Medicines Agency · EMEA/H/C/004085 · revised May 7, 2026
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.